Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

Stocks: Insiders Buy at 4 Biotechs -- Dicerna, Ultragenyx, Regulus, and Cara

By

Regulus Therapeutics renewed its strategic alliance with French pharmaceutical company Sanofi, which added $10 million in equity to its stake in the firm.

PrintPRINT
Welcome to our daily roundup of top insider trades. Here's a look at the most significant inside purchases recently filed with the SEC.

Notable Purchases:
  • The Boston-based private equity firm Ra Capital Management bought 1,000,000 shares of biopharmaceutical company Dicerna Pharmaceuticals (NASDAQ:DRNA) for $15,000,000. Dicerna focuses on the discovery and development of treatment for rare, inherited diseases of the liver, as was as cancers that are genetically defined.
  • The American financial services company FMR LLC, also known as Fidelity Investments, bought 175,000 shares of development-stage biopharmaceutical company Ultragenyx Pharmaceuticals (NASDAQ:RARE) for $3,675,000. Ultragenyx is focused on the identification, acquisition, development, and commercialization of treatments for rare and ultra-rare diseases.
  • The investment firm Rho Ventures VI bought 225,818 shares of clinical-stage biopharmaceutical company Cara Therapeutics (NASDAQ:CARA) for $2,483,998. Cara focuses on the development and commercialization of chemical therapeutics designed to alleviate pain.
For more insider trades, see the charts below.

Insider Purchases
#: Filer Name Insider Titles Company Name Ticker Trans
Type
Dollar Value
1
PR,BO
JB*
$15,000,000
2
BO
JB*
$9,999,993
3
BO
JB*
$3,675,000
4
BO
B
$2,488,255
5
BO
JB*
$2,483,998
6
DIR,BO
B
$554,604
7
DIR
JB*
$550,000
8
DIR
B
$352,050
9
CEO,CB,BO
B
$330,645
10
CEO,DIR
JB*
$324,987

Insider Sales
#: Filer Name Insider Titles Company Name Ticker Trans
Type
Dollar Value
1
F,DIR,BO
AS
$95,403,792
2
CB,DIR
JS*
$26,546,699
3
F,CEO,CB
S
$17,935,374
4
DIR,BO
AS
$17,684,010
5
BO
JS*
$15,675,000
6
DIR
JS*
$14,787,500
7
DIR
JS*
$9,500,000
8
CEO,DIR
AS
$7,851,817
9
DIR
S
$6,206,220
10
CB,DIR,BO
S
$6,005,230

Source: InsiderInsights.com | Key to Insider Title and Trans Type Codes

An important note from Jonathan Moreland, founder of Insider Insights:

In a victory for common sense, it has been proven profitable -- by both academic studies and (more importantly) the experience of your fellow professional investors -- to monitor the trading behavior of company executives, directors, and large shareholders in the stocks of firms of which they're registered as "insiders."

Please note, however, that the lists above are strictly factual; they are not buy and sell recommendations. Dollar value is only one metric to assess the importance of an insider transaction, and, frankly, often not even the most important metric that determines if an insider transaction is significant.

At InsiderInsights.com, we find new investment ideas just about every day using these and more intricate insider screens to determine where we should focus our subsequent fundamental and technical analysis. And while stocks don't (or shouldn't) move up or down based on insider activity alone, insiders tend to be good indicators of when real stock-moving events like earnings surprises, corporate actions, and new products may be in the offing.

Jonathan Moreland is also the author of "Profit From Legal Insider Trading."
No positions in stocks mentioned.
PrintPRINT
 
Featured Videos

WHAT'S POPULAR IN THE VILLE